Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: Hepatology. 2014 Aug 13;60(4):1160–1169. doi: 10.1002/hep.27092

Table 1.

Characteristics of studied patient groups.

	Ribavirin Pretreatment (n = 22)	No Ribavirin Pretreatment (n = 32)	p-value
Early virological responders (EVR), n (%)	17 (77%)	29 (88%)	0.298
Sustained virological responders (SVR), n (%)	11 (50%)	18 (56%)	0.741
Gender (male/female)	13/9	20/13	0.911
Age at Start of Therapy, mean (±SD) years	49.6 (±12.8)	51.9 (±8.5)	0.612
Ethnicity (Asian/African-American/Hispanic/Caucasian)	4/3/0/15	6/7/2/18	0.979/0.627/0.434/0.503
Body mass index, mean (±SD)	29 (±6.0)	29.2 (±6.9)	0.9314
IL-28B rs12979860 SNP (CC vs. CT/TT)	9/11	14/13	0.2974
Genotype (1/2/3/4/6)	12/3/4/1/2	18/7/5/3/0	1/0.724/1/0.642/0.173
Serum HCV RNA titer at start of treatment, mean (±SD) log₁₀ IU/ml	6.4 (±0.6)	6.3 (±0.7)	0.843
ALT at start of therapy, mean (±SD) U/L	104 (±78.6)	103 (±93)	0.884
Ishak Inflammatory Score, mean (±SD)	7.6 (±2.8)	7.4 (±2.2)	0.797
Ishak Fibrosis Score, mean (±SD)	2.2 (±2.2)	2.1 (±2.1)	0.768

SNP, single nucleotide polymorphism